CHICAGO--(BUSINESS WIRE)-- Bruker Corporation (BRKR) (Nasdaq: BRKR) announced today that it will unveil significant advancements in spatial biology and multiomics research at the 2025 American ...

Bruker now extends their complete biology approach to mouse research by announcing development of the CosMx Mouse Whole Transcriptome (WTX) assay. The mouse WTX assay will be available for both FFPE ...

Advancements to include CosMx® Whole Transcriptome Panel; enhanced technology engine to power CellScape™ for spatial proteomics; expansion to 1000-plex protein assay on GeoMx® DSP; and launch of ...

Bruker Spatial Biology and Noetik are expanding a collaboration involving foundational models for therapeutics applications.

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years. Now under a single operational banner, it includes the company’s previous Bruker ...

Available later this quarter, the commercial CosMx SMI and AtoMx® SIP platforms will be upgraded to an integrated 2.0 software. Following this upgrade, commercial CosMx SMI instruments will deliver up ...

The Whole Transcriptome Panel for Bruker’s CosMx Spatial Molecular Imager (SMI) represents a breakthrough in spatial biology. With the ability to detect and quantify over 18,000 RNA transcripts at ...

Portfolio innovations include the launch of the new CellScape XR spatial proteomics platform, the unique CosMx mouse whole transcriptome panel, the launch of the PaintScape platform for 3D genome ...